ArticleRadiology and oncology2014

Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations.

Matjaz Zwitter et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.